<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Chen YL</submitter><funding>Guangdong Medical Scientific Research Foundation</funding><funding>Natural Science Foundation of Guangdong Province</funding><funding>National Natural Science Foundation of China</funding><funding>Key Program of Young Teachers Foundation of Sun Yat-sen University</funding><pagination>81</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5932798</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>20(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Previous studies have revealed that hepatitis B virus (HBV) infection may be associated with rheumatoid arthritis (RA), while there are no further clinical studies regarding the role of HBV infection in RA progression during disease-modifying anti-rheumatic drug (DMARD) therapy. Here, we aimed to explore the influence of HBV infection on radiographic and clinical outcomes among patients with RA in a clinical practice setting.&lt;h4>Methods&lt;/h4>Thirty-two consecutive patients with RA (Disease Activity Score 28-joint assessment based on C-reactive protein (DAS28-CRP) ≥2.6) with chronic HBV infection (CHB) were retrospectively recruited as the CHB group and 128 age-matched, sex-matched, and disease activity-matched contemporary patients with RA without CHB were included in the</pubmed_abstract><journal>Arthritis research &amp; therapy</journal><pubmed_title>Deleterious role of hepatitis B virus infection in therapeutic response among patients with rheumatoid arthritis in a clinical practice setting: a case-control study.</pubmed_title><pmcid>PMC5932798</pmcid><funding_grant_id>2016A030313307</funding_grant_id><funding_grant_id>17ykjc12</funding_grant_id><funding_grant_id>81471597</funding_grant_id><funding_grant_id>81671612</funding_grant_id><funding_grant_id>2017A030313576</funding_grant_id><funding_grant_id>A2017109</funding_grant_id><funding_grant_id>81601427</funding_grant_id><funding_grant_id>2014A030313074</funding_grant_id><pubmed_authors>Yang ZH</pubmed_authors><pubmed_authors>Dai L</pubmed_authors><pubmed_authors>Lin JZ</pubmed_authors><pubmed_authors>Li QH</pubmed_authors><pubmed_authors>Mo YQ</pubmed_authors><pubmed_authors>Yan T</pubmed_authors><pubmed_authors>Zheng DH</pubmed_authors><pubmed_authors>Chen YL</pubmed_authors><pubmed_authors>Ma JD</pubmed_authors><pubmed_authors>Wang XY</pubmed_authors></additional><is_claimable>false</is_claimable><name>Deleterious role of hepatitis B virus infection in therapeutic response among patients with rheumatoid arthritis in a clinical practice setting: a case-control study.</name><description>&lt;h4>Background&lt;/h4>Previous studies have revealed that hepatitis B virus (HBV) infection may be associated with rheumatoid arthritis (RA), while there are no further clinical studies regarding the role of HBV infection in RA progression during disease-modifying anti-rheumatic drug (DMARD) therapy. Here, we aimed to explore the influence of HBV infection on radiographic and clinical outcomes among patients with RA in a clinical practice setting.&lt;h4>Methods&lt;/h4>Thirty-two consecutive patients with RA (Disease Activity Score 28-joint assessment based on C-reactive protein (DAS28-CRP) ≥2.6) with chronic HBV infection (CHB) were retrospectively recruited as the CHB group and 128 age-matched, sex-matched, and disease activity-matched contemporary patients with RA without CHB were included in the</description><dates><release>2018-01-01T00:00:00Z</release><publication>2018 May</publication><modification>2025-05-29T21:21:42.003Z</modification><creation>2025-05-29T21:21:42.003Z</creation></dates><accession>S-EPMC5932798</accession><cross_references><pubmed>29720221</pubmed><doi>10.1186/s13075-018-1548-5</doi></cross_references></HashMap>